Annovis Bio

[On Demand]
Search General Info
Search Education
Search Partnering Companies
Annovis Bio, Inc. is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer's disease (AD), Parkinson's disease (PD) and Alzheimer's in Down Syndrome (AD-DS). We believe that we are the only company developing a drug for AD, PD and AD-DS that inhibits more than one neurotoxic protein and, thereby, improves the information highway of the nerve cell, known as axonal transport. When this information flow is impaired, the nerve cell gets sick and dies. We expect our treatment to improve memory loss and dementia associated with AD and AD-DS, as well as body and brain function in PD.
Ticker:
ANVS
Exchange:
NYSE American
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
Pennsylvania
Company HQ Country:
United States
Year Founded:
2008
Main Therapeutic Focus:
Lead Product in Development:
ANVS401
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
President & CEO
Annovis Bio, Inc.